Combination tumor immunotherapy
US10682365B2 · kind B2 · utility
7Cited by
51References
15Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 22, 2015 |
| Grant date | Jun 16, 2020 |
| Priority date | — |
| Expiry date | Dec 22, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.